Immunoglobulin Therapy for Plasma Cell-Rich Rejection in the Renal Allograft
- 27 August 2006
- journal article
- case report
- Published by Wolters Kluwer Health in Transplantation
- Vol. 82 (4) , 567-569
- https://doi.org/10.1097/01.tp.0000231922.11453.ec
Abstract
Plasma cell-rich acute rejection (PCAR) is associated with poor allograft outcome in renal transplantation. Previous studies report a graft half-life of six months after a single PCAR episode. However, the management of this condition is unclear. Intravenous immunoglobulin (IVIG) therapy, by virtue of its immunomodulating properties, and its influence on B-cell maturation into plasma cells, may be a good candidate for reversing this type of rejection. We report four episodes of PCAR in two patients who responded well to IVIG with improvement in renal function.Keywords
This publication has 8 references indexed in Scilit:
- Renal graft loss with plasma cell‐rich acute rejection in cadaveric renal transplantation: a case reportClinical Transplantation, 2005
- Consensus Opinion from the Antibody Working Group on the Diagnosis, Reporting, and Risk Assessment for Antibody-Mediated Rejection and Desensitization ProtocolsTransplantation, 2004
- Acute renal allograft rejections with major interstitial oedema and plasma cell-rich infiltrates: high -interferon expression and poor clinical outcomeNephrology Dialysis Transplantation, 2004
- Desensitization and Subsequent Kidney Transplantation of Patients Using Intravenous Immunoglobulins (IVIg)American Journal of Transplantation, 2002
- Immunomodulation of Autoimmune and Inflammatory Diseases with Intravenous Immune GlobulinNew England Journal of Medicine, 2001
- The clinical and pathologic implications of plasmacytic infiltrates in percutaneous renal allograft biopsiesHuman Pathology, 2001
- PLASMA CELL-RICH ACUTE RENAL ALLOGRAFT REJECTION1Transplantation, 1999
- Importance of Plasma Cells in the Infiltrate of Renal Allografts: An Immunohistochemical StudyPathology - Research and Practice, 1991